Real-world assessment of the impact of neighborhood vulnerabilities on prostate cancer outcomes in the Medstar Health Network.

J Jeffrey Riskin (Medstar Georgetown University Hospital, Washington, DC) Y Yanbao Xiong (MedStar Georgetown University Medical Center, Washington, DC) S Sravya Jannapureddy (Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC) R Rachel Alexander (MedStar Georgetown University Medical Center, Washington, DC) N Nilansh Kataria (MedStar Washington Hospital Center, Washington, DC) S Suraj Singh B Bassem R. Haddad (Georgetown University Medical Center, Washington, DC) M Mary Beth Martin (Georgetown University Medical Center, Washington, DC) A Adil Adil Alaoui (Georgetown University Medical Center, Washington, DC) Y Yuriy Gusev K Kepher Makambi (Georgetown University Medical Center, Washington, DC) G Gregory Dyson (Karmanos Cancer Institute/Department of Oncology, Detroit, MI) N Nancy Ann Dawson (Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC) P Paul Denis Leger (Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC)

Abstract

e17140 Background: The disparities in prostate cancer (PC) treatment outcomes are thought to be multifactorial, resulting from complex interactions between social determinants of health (SDoH), disease biology, and healthcare-related factors. The impact of SDoH on PC mortality remains unclear. This study examines whether equal access to standard of care eliminates outcome disparities among men with advanced PC in the Medstar Health Network. Methods: This is a retrospective analysis of factors associated with treatment outcomes among men with advanced PC who received standard of care treatment in the Medstar Health Network from 2014-2025. Social Vulnerability Index (SVI) was used as a validated tool to quantify patients’ vulnerabilities. We compared age, disease stage at diagnosis, mortality between the highest (Q4) and lowest (Q1) vulnerability quartiles and between racial groups using chi-squared tests and t-tests. Results: We identified a cohort of 360 men diagnosed with PC which included 166 (46.1%) Black and 139 (38.6%) White patients. Median age was 73 years (IQR 66-80). Staging data were available for 281 patients, with 215 (78%) initially diagnosed with stage IV disease. SVI data were collected for 324 (90%) patients and Gleason scores were available for 239 (66.4%) patients. Median treatment follow-up was 26 months (IQR 10.8-53.7). A total of 116 patients (32.8%) died. SVI and outcomes: Significant differences were observed between Q1 and Q4 groups in stage IV diagnosis rates (Q4 areas 85% vs Q1 areas 64.7%, p = 0.012, OR = 3.21). However, mortality was equivalent between groups (32.1% vs 34.6%, p = 0.87) as was age at diagnosis (70.8 vs 72.3 years, p = 0.30). Race and Outcomes: Stage IV diagnosis rates were similar between Black and White patients (77.7% vs 72.3%, p = 0.41). However, Black patients were diagnosed significantly younger (mean age 70.3 vs 74.6 years, p = 0.0001), with a mean difference of 4.3 years. Mortality rates were comparable (33.3% vs 37.2%, p = 0.56). Black patients resided in significantly more disadvantaged areas (mean SVI 0.545 vs 0.316, p = 0.0001). Conclusions: Among patients treated at the Medstar Health Network, there were significant racial disparities in age at diagnosis, whereas patients in disadvantaged areas were more likely to be diagnosed with stage IV disease. However, no significant differences in mortality were observed by race or SVI. These findings suggest that equitable access to high-quality care may mitigate outcome disparities despite persistent contextual disadvantages. This dataset has limitations related to its retrospective nature and its limited sample size. However, these results are consistent with prior studies that demonstrate similar outcomes between populations when patients receive standard of care. This study adds rationale to promote health equity, ensuring broader access to screening and treatment to minority populations.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (14)

J

Jeffrey Riskin

Medstar Georgetown University Hospital, Washington, DC

Y

Yanbao Xiong

MedStar Georgetown University Medical Center, Washington, DC

S

Sravya Jannapureddy

Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC

R

Rachel Alexander

MedStar Georgetown University Medical Center, Washington, DC

N

Nilansh Kataria

MedStar Washington Hospital Center, Washington, DC

S

Suraj Singh

B

Bassem R. Haddad

Georgetown University Medical Center, Washington, DC

M

Mary Beth Martin

Georgetown University Medical Center, Washington, DC

A

Adil Adil Alaoui

Georgetown University Medical Center, Washington, DC

Y

Yuriy Gusev

K

Kepher Makambi

Georgetown University Medical Center, Washington, DC

G

Gregory Dyson

Karmanos Cancer Institute/Department of Oncology, Detroit, MI

N

Nancy Ann Dawson

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC

P

Paul Denis Leger

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC